Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical review

Clinical Therapeutics

Volumn 25, Issue 7, 2003, Pages 1952-1974

  Rivkin, Anastasia ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Constipation; Irritable bowel syndrome; Tegaserod maleate

Indexed keywords

ANTIDEPRESSANT AGENT; BENZAMIDE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DEXTROMETHORPHAN; DICYCLOVERINE; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HYOSCYAMINE; ISPAGULA; METHYLCELLULOSE; PLACEBO; POLYCARBOPHIL CALCIUM; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; BACKACHE; CHOLELITHIASIS; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; FIBROMA; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; LONG TERM CARE; MEDLINE; NAUSEA; OVARY CYST; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; REVIEW; STOMACH MOTILITY; TERATOGENICITY; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0041701536     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80198-4     Document Type: Article

References (91)

1. Talley NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: Symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 1995;142:76-83.
2. Zaman M, Chavez N, Krueger R, et al. Extra-intestinal symptoms in patients with irritable bowel syndrome (IBS). Gastroenterology. 2001;120:A636. Abstract.
3. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology. 2001;120:652-668.
4. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(Suppl 11):S1-S5.
5. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med. 2001;344:1846-1850.
6. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
7. Bjorkman D. IBS: Counting the clinical and economic cost. In: Program and abstracts of the 67th Annual Scientific Meeting of the American College of Gastroenterology; October 21-23, 2002; Seattle, Wash.
8. Patel RP, Petitta A, Fogel R, et al. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol. 2002;35:14-20.
9. Leong S, Barghout V, Birnbaum H, et al. Economic outcomes of irritable bowel syndrome: An employer perspective. Am J Gastroenterol. 2001;96:S320. Abstract.
10. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2:653-654.
11. Drossman D, Corazziari E, Talley N, et al. Rome II: A multinational consensus document on functional gastrointestinal disorders. Gut. 1999;45:1-81.
12. Badiali D, Altobelli G, Corazziari E. Reclassification of functional bowel disorders with Rome II diagnostic criteria. Gastroenterology. 2001;120:A755. Abstract.
13. De Ponti F, Tonini M. Irritable bowel syndrome: New agents targeting serotonin receptor subtypes. Drugs. 2001;61:317-332.
14. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology. 2002;123:1686-1701.
15. Bazzocchi G, Ellis J, Villanueva-Meyer J, et al. Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology. 1991;101:1298-1306.
16. Bazzocchi G, Ellis J, Villanueva-Meyer J, et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology. 1990;98:686-693.
17. Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: Relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405-411.
18. Vassallo M, Camilleri M, Phillips SF, et al. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology. 1992;102:102-108.
19. Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology. 1991;101:107-115.
20. Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: Differences between diarrhoea and constipation predominant subjects. Gut. 1990;31:458-462.
21. 3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:543-551.
22. Vassallo MJ, Camilleri M, Phillips SF, et al. Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc. 1992;67:725-731.
23. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92:1885-1893.
24. Gorard DA, Libby GW, Farthing MJ. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome. Gut. 1994;35:203-210.
25. Schmidt T, Hackelsberger N, Widmer R, et al. Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 1996;31:581-589.
26. Evans PR, Bennett EJ, Bak YT, et al. Jejunal sensorimotor dysfunction in irritable bowel syndrome: Clinical and psychosocial features. Gastroenterology. 1996;110:393-404.
27. Camilleri M, Neri M. Motility disorders and stress. Dig Dis Sci. 1989;34:1777-1786.
28. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973;14:125-132.
29. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40-52.
30. Lembo T, Munakata J, Naliboff B, et al. Sigmoid afferent mechanisms in patients with irritable bowel syndrome. Dig Dis Sci. 1997;42:1112-1120.
31. Schmulson M, Chang L, Naliboff B, et al. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. Am J Gastroenterol. 2000;95:152-156.
32. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7(Suppl 8):S252-S260.
33. Wrzos H, Guillaume M, Norgren R, et al. c-fos Protein expression in the brain of the anesthetized rat induced by colorectal distention. Gastroenterology. 2001;120:A715. Abstract.
34. Kozlowski CM, Green A, Grundy D, et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut. 2000;46:474-480.
35. Howell S, Poulton R, Talley N. Is psychiatric illness, personality or both a predictor of IBS in young adults? Results from a birth cohort study in New Zealand. Gastroenterology. 2001;120:A114. Abstract.
36. Dickhaus B, Firooz N, Stains J, et al. Psychological stress increases visceral sensitivity in patients with irritable bowel syndrome (IBS) but not controls. Gastroenterology. 2001;120:A67. Abstract.
37. Palsson O, Turner M, Davies M, et al. Vasoactive intestinal peptide levels are elevated in the blood plasma of irritable bowel syndrome (IBS) patients. Gastroenterology. 2001;120:A718. Abstract.
38. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study. Gut. 1998;42:42-46.
39. Bose M, Nickols C, Feakins R, Farthing M. 5-Hydroxytryptamine and enterochromaffin cells in the irritable bowel syndrome. Gastroenterology. 2000;118:A563. Abstract.
40. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347:150-153.
41. Spiller R, Jenkins D, Thornley J, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-811.
42. Hollerbach S, Kizil F, Reiser M, et al. IBS patients exhibit subtle differences in the composition of the residual colonic inflammatory infiltrate. Gastroenterology. 2002;122:A319. Abstract.
43. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study. BMJ. 1999;318:565-566.
44. McKendrick MW, Read NW. Irritable bowel syndrome - post Salmonella infection. J Infect. 1994;29:1-3.
45. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: A six year follow up study. Gut. 2002;51:410-413.
46. Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm. 2000;57:1685-1697.
47. 3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol. 1992;59:221-226.
48. 3 receptor antagonist, prevents cisplatin-induced emesis in dogs. Methods Find Exp Clin Pharmacol. 1989;11:361-363.
49. 3 Receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989;97:247-255.
50. 4 receptor agonists stimulate small intestinal transit but do not have direct visceral antinociceptive effects in the rat. Gastroenterology. 2001;120:A6. Abstract.
51. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Gastroenterology. 2002;122:A311. Abstract.
52. Frissora CL. A new look at irritable bowel syndrome (IBS): A neuroenteric disorder. Compr Ther. 2002;28:222-231.
53. Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut. 1984;25:168-173.
54. Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92:95-98.
55. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:499-510.
56. Pfannkuche HJ, Buhl T, Gamse R, Hoyer D, et al. The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastroenterol Motil. 1995;7:280. Abstract.
57. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet. 2002;41:1021-1042.
58. 4 agonist. J Clin Gastroenterol. 2002;34:27-33.
59. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology. 1998;115:370-380.
60. 4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol. 1999;47:483-491.
61. Zhou H, Khalilieh S, Lau H, et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol. 1999;39:911-919.
62. Appel-Dingemanse S, Hubert M, Alladina L, et al. Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug, in healthy subjects and in patients with hepatic cirrhosis. Digestion. 1998;59:736. Abstract.
63. Zhou H, McLeod J, Alladina L, et al. Pharmacokinetics of SDZ HTF 919 not altered in subjects with severe renal insufficiency requiring hemodialysis. Clin Pharmacol Ther. 1999;65:203. Abstract.
64. Appel-Dingemanse S, Horowitz A, Campestrini J, et al. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young. Aliment Pharmacol Ther. 2001;15:937-944.
65. Zelnorm™ [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.
66. Camilleri M. Review article: Tegaserod. Aliment Pharmacol Ther. 2001;15:277-289.
67. Vickers AE, Zollinger M, Dannecker R, et al. In vitro metabolism of tegaserod in human liver and intestine: Assessment of drug interactions. Drug Metab Dispos. 2001;29:1269-1276.
68. Zhou H, Khalilieh S, Svendsen K, et al. Tegaserod coadrninistration does not alter the pharmacokinetics of theophylline in healthy subjects. J Clin Pharmacol. 2001;41:987-993.
69. Kalbag J, Migoya E, Osborn S, Lasseter K, et al. Tegaserod does not significantly affect the pharmacokinetics of dextromethorphan in healthy subjects. Gastroenterology. 2000;118 (Suppl 2):5422. Abstract.
70. Ledford PC, Ligueros-Saylan M, Campestrini J, Osborne S. Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Gastroenterology. 2000;118:A1184. Abstract.
71. Zhou H, Walter Y, Hubert M, et al. Tegaserod (HTF919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects. Gastroenterology. 2000;118:A1207. Abstract.
72. Zhou H, Horowitz A, Ledford PC, et al. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J Clin Pharmacol. 2001;41:1131-1139.
73. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther. 1997;280:1270-1276.
74. Scarpignato C, Pelosini I. Management of irritable bowel syndrome: Novel approaches to the pharmacology of gut motility. Can J Gastroenterol. 1999;13(Suppl A):50A-65A.
75. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15:1745-1751.
76. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463-468.
77. Kamm MA. Review article: The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:343-351.
78. Northcuff A, Mangel A, Hamm L, et al. Persistent placebo response during a year-long controlled trial of IBS treatment. Gastroenterology. 2001;120:A640. Abstract.
79. Lacy BE. Tegaserod. Clin Perspectives Gastroenterol. 2002;5:251-255.
80. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666.
81. 4 partial agonist tegaserod improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome. Am J Gastroenterol. 1999;94:A396. Abstract.
82. 4 agonist, improves abdominal bloating and altered stool consistency in irritable bowel syndrome (IBS). Am J Gastroenterol. 1999;94:A432. Abstract.
83. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888.
84. Schoenfeld P, Chey W, Drossman D, et al. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: A meta-analysis of randomized controlled trials. Gastroenterology. 2002;122:A465. Abstract.
85. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol. 1999;34:82-88.
86. 4 receptor partial agonist, is devoid of significant electrocardiographic effects. Gastroenterology. 2001;120:A643. Abstract.
87. Morganroth J, Rueegg PC, Dunger-Baldauf C, et al. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol. 2002;97:2321-2327.
88. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1701-1708.
89. Fidelhohz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol. 2002;97:1176-1181.
90. Drug Topics Redbook. Montvale, NJ: Medical Economics Company; 2002.
91. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(Suppl 11):S7-S26.